Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 5, 2014, Pages 751-758

  Wu, Lingzhen ^a   Fang, Jun ^a   Chen, Lianglong ^a   Zhao, Ziwen ^a   Luo, Yukun ^a   Lin, Chaogui ^a   Fan, Lin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

adropin; atherosclerosis; coronary artery disease; type 2 diabetes

Indexed keywords

ADROPIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEIN; UNCLASSIFIED DRUG; ENHO PROTEIN, HUMAN; PEPTIDE; PLASMA PROTEIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRIESINGER SCORE; GENSINI SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SYNTAX SCORE; SYSTOLIC BLOOD PRESSURE; AGED; COMPLICATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; RADIOGRAPHY; RISK; STATISTICAL MODEL;

AGED; BLOOD PROTEINS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDES;

EID: 84898941309     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0844     Document Type: Article

References (26)

1. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al., American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-26. (Pubitemid 46058619)
2. Sanz J, Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2011;58:779-91.
3. Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 2011;34:1337-43.
4. Mazzone T, Meyer PM, Kondos GT, Davidson MH, Feinstein SB, D′Agostino RB Sr, et al. Relationship of traditional and nontra-ditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes 2007;56:849-55. (Pubitemid 46348462)
5. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011;34(Suppl 2):S285-90.
6. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009;32(Suppl 2):S314-21.
7. Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O′Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 2003;23:1035-41. (Pubitemid 36713557)
8. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008;8:468-81.
9. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation 2010;122(Suppl):S185-92.
10. Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring) 2012;20:1394-402.
11. American Diabetes Association: diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-9.
12. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606. (Pubitemid 13187192)
13. Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, et al. Prognostic value of angiographic indices of coronary artery disease from the coronary artery surgery study (CASS). J Clin Invest 1983;71:1854-66. (Pubitemid 13056789)
14. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroInter-vention 2005;1:219-27.
15. Brugaletta S, Magro M, Simsek C, Heo JH, de Boer S, Ligthart J, et al. Plaque compositional Syntax score: combining angiography and lipid burden in coronary artery disease. JACC Cardiovasc Imaging 2012;5(Suppl 3):S119-21.
16. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32.
17. Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010;170:478-84.
18. Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O′Keeffe M, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab 2012;97:3783-91.
19. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8. (Pubitemid 33108132)
20. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010;33:442-9.
21. Celik E, Yilmaz E, Celik O, Ulas M, Turkcuoglu I, Karaer A, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med 2013;9:1-6.
22. Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, et al. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 2013;31:174-8.
23. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9. (Pubitemid 36158034)
24. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoom Study. Arterioscler Thromb Vasc Biol 1999;19:3071-8. (Pubitemid 30029838)
25. Taniguchi H, Momiyama Y, Ohmori R, Yonemura A, Yamashita T, Tamai S, et al. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease. Atherosclerosis 2005;178:173-7. (Pubitemid 39600830)
26. Noren Hooten N, Ejiogu N, Zonderman AB, Evans MK. Association of oxidative DNA damage and C-reactive protein in women at risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 2012;32:2776-84.